share_log

复旦张江(1349.HK)调研纪要

國元(香港) ·  Dec 17, 2013 16:00  · Researches

Researcher brief comment: The company is mainly engaged in innovative research, development, production and sales of biomedicine, and is a biomedical innovation enterprise with intellectual property as the core. The company continues to launch new technologies and products in the fields of genetically engineered drugs, photodynamic drugs, and nanopharmaceuticals, etc., forming a clear competitive advantage, and it is expected that new drugs will be launched on the market one after another in the future. The company officially switched from GEM to Main Board trading at 9 o'clock on December 16, 2013, and the code was changed from 8231.HK to 1349.HK. We believe this is an important milestone in the company's development. The company hopes to become a benchmark enterprise in the photopower field and maintain a good growth trend in the future. Investors are advised to keep a close eye on it.

The translation is provided by third-party software.


The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.
    Write a comment

    Statement

    This page is machine-translated. Futubull tries to improve but does not guarantee the accuracy and reliability of the translation, and will not be liable for any loss or damage caused by any inaccuracy or omission of the translation.